Research Article
The Correlation between PSCA Expression and Neuroendocrine Differentiation in Prostate Cancer
Table 5
Univariate and multivariate Cox logistic regression analysis of overall survival in patients with prostate cancer.
| Clinicopathological features | Univariate | Multivariate | HR | 95% CI | value | HR | 95% CI | value |
| Age | 1.308 | 0.563-3.039 | 0.533 | | | | Preoperative PSA level | 1.328 | 0.783-2.253 | 0.293 | | | | Gleason score | 2.313 | 1.299-4.118 | 0.004 | 1.347 | 0.630-2.878 | 0.442 | pT stage | 1.538 | 0.672-3.520 | 0.308 | | | | Metastasis status | 3.363 | 1.390-8.134 | 0.007 | 1.572 | 0.564-4.387 | 0.387 | Hormone therapy | 0.306 | 0.072-1.308 | 0.110 | | | | PSCA expression level | 10.068 | 1.355-74.805 | 0.024 | 4.250 | 0.466-38.734 | 0.199 | NSE expression level | 3.841 | 1.647-8.957 | 0.002 | 1.711 | 0.638-4.584 | 0.286 | Surgical intervention | 2.346 | 1.014-5.428 | 0.046 | 1.750 | 0.730-4.192 | 0.210 |
|
|
Abbreviations: HR: hazard ratio; CI: confidence interval; pT stage: pathologic tumor stage; PSCA: prostate stem cell antigen; NSE: enolase 2.
|